{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T14:18:06Z","timestamp":1793369886995,"version":"4.5.0"},"reference-count":105,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.neuropharm.2026.111013","type":"journal-article","created":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T15:27:28Z","timestamp":1778340448000},"page":"111013","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["PACAP in Parkinson's disease: A multifunctional neuropeptide at the crossroad of autophagy, inflammation, and metabolic repurposing"],"prefix":"10.1016","volume":"296","author":[{"given":"Manal Ewaiss","family":"Hassan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hayder M.","family":"Al-kuraishy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3025-2343","authenticated-orcid":false,"given":"Mohamed N.","family":"Fawzy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nawar R.","family":"Hussain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali I.","family":"Al-Gareeb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eman K.","family":"Rashwan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali K.","family":"Albuhadily","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaber El-Saber","family":"Batiha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2026.111013_bib1","doi-asserted-by":"crossref","first-page":"166","DOI":"10.4103\/bbrj.bbrj_7_20","article-title":"Oxidative stress injury and glucolipotoxicity in type 2 diabetes mellitus: the potential role of metformin and sitagliptin","volume":"4","author":"Abdul-Hadi","year":"2020","journal-title":"Biomedical and Biotechnology Research Journal (BBRJ)"},{"key":"10.1016\/j.neuropharm.2026.111013_bib2","doi-asserted-by":"crossref","first-page":"46","DOI":"10.4103\/ijp.IJP_384_20","article-title":"Neuroprotective effects of linagliptin in a rotenone-induced rat model of Parkinson's disease","volume":"54","author":"Abhangi","year":"2022","journal-title":"Indian J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2026.111013_bib3","doi-asserted-by":"crossref","DOI":"10.1111\/ejn.70067","article-title":"The possible role of metformin and fibroblast growth Factor\u201021 in multiple sclerosis neuropathology: birds of a feather flock together","volume":"61","author":"Abulaban","year":"2025","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.neuropharm.2026.111013_bib4","doi-asserted-by":"crossref","first-page":"398","DOI":"10.3390\/ijms23010398","article-title":"Metformin repurposing for parkinson disease therapy: opportunities and challenges","volume":"23","author":"Agostini","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.neuropharm.2026.111013_bib5","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1007\/s43441-024-00637-2","article-title":"Safety of linagliptin in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized clinical trials","volume":"58","author":"Aljohani","year":"2024","journal-title":"Ther. Innov. Regul. Sci."},{"key":"10.1016\/j.neuropharm.2026.111013_bib6","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2025.1497261","article-title":"Randomized, double-blind, placebo-controlled pilot study of metformin as an adjunctive therapy in Parkinson's disease","volume":"16","author":"AlRasheed","year":"2025","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.neuropharm.2026.111013_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2025.110555","article-title":"Berberine's paradox in Neurodegeneration: therapeutic promise and safety challenges in Parkinson's disease","volume":"278","author":"Alshahrani","year":"2025","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2026.111013_bib8","doi-asserted-by":"crossref","DOI":"10.3389\/fddsv.2021.818003","article-title":"Design and synthesis of brain penetrant glycopeptide analogues of PACAP with neuroprotective potential for traumatic brain injury and parkinsonism","volume":"1","author":"Apostol","year":"2022","journal-title":"Frontiers in Drug Discovery"},{"key":"10.1016\/j.neuropharm.2026.111013_bib9","doi-asserted-by":"crossref","first-page":"4932","DOI":"10.3390\/molecules26164932","article-title":"Synthesis and in vitro characterization of glycopeptide drug candidates related to PACAP1\u201323","volume":"26","author":"Apostol","year":"2021","journal-title":"Molecules"},{"key":"10.1016\/j.neuropharm.2026.111013_bib10","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1002\/mds.30067","article-title":"Environmental risk factors for parkinson's disease: a critical review and Policy implications","volume":"40","author":"Atterling Brolin","year":"2024","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neuropharm.2026.111013_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2025.124176","article-title":"PACAP: a promising disease-modifying target for Alzheimer's disease","volume":"386","author":"Basri","year":"2026","journal-title":"Life Sci."},{"key":"10.1016\/j.neuropharm.2026.111013_bib12","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1111\/j.1471-4159.2011.07330.x","article-title":"Pituitary adenylate cyclase\u2010activating peptide induces long\u2010lasting neuroprotection through the induction of activity\u2010dependent signaling via the cyclic AMP response element\u2010binding protein\u2010regulated transcription co\u2010activator 1","volume":"118","author":"Baxter","year":"2011","journal-title":"J. Neurochem."},{"key":"10.1016\/j.neuropharm.2026.111013_bib13","doi-asserted-by":"crossref","DOI":"10.3389\/fnmol.2024.1443985","article-title":"Peptide discovery across the spectrum of neuroinflammation; microglia and astrocyte phenotypical targeting, mediation, and mechanistic understanding","volume":"17","author":"Benita","year":"2024","journal-title":"Front. Mol. Neurosci."},{"key":"10.1016\/j.neuropharm.2026.111013_bib14","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/j.cellsig.2006.12.006","article-title":"PACAP stimulates the sustained phosphorylation of tyrosine hydroxylase at serine 40","volume":"19","author":"Bobrovskaya","year":"2007","journal-title":"Cell. Signal."},{"key":"10.1016\/j.neuropharm.2026.111013_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.peptides.2021.170554","article-title":"PACAP orchestration of stress-related responses in neural circuits","volume":"142","author":"Boucher","year":"2021","journal-title":"Peptides (N.Y.)."},{"key":"10.1016\/j.neuropharm.2026.111013_bib16","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1007\/s12031-022-01968-1","article-title":"PACAP and VIP mitigate rotenone-induced inflammation in BV-2 microglial cells","volume":"72","author":"Broome","year":"2022","journal-title":"J. Mol. Neurosci."},{"key":"10.1016\/j.neuropharm.2026.111013_bib17","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1007\/s12640-014-9468-x","article-title":"PACAP protects against inflammatory-mediated toxicity in dopaminergic SH-SY5Y cells: implication for parkinson's disease","volume":"26","author":"Brown","year":"2014","journal-title":"Neurotox. Res."},{"key":"10.1016\/j.neuropharm.2026.111013_bib18","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1007\/s12031-013-0015-7","article-title":"PACAP protects against salsolinol-induced toxicity in dopaminergic SH-SY5Y cells: implication for parkinson's disease","volume":"50","author":"Brown","year":"2013","journal-title":"J. Mol. Neurosci."},{"key":"10.1016\/j.neuropharm.2026.111013_bib19","doi-asserted-by":"crossref","first-page":"9453","DOI":"10.3390\/ijms25179453","article-title":"Increased expression of the neuropeptides PACAP\/VIP in the brain of mice with CNS targeted production of IL-6 is mediated in part by trans-signalling","volume":"25","author":"Castorina","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.neuropharm.2026.111013_bib20","doi-asserted-by":"crossref","first-page":"923","DOI":"10.4103\/1673-5374.232489","article-title":"Inhibition of retinal ganglion cell apoptosis: regulation of mitochondrial function by PACAP","volume":"13","author":"Cheng","year":"2018","journal-title":"Neural Regen. Res."},{"key":"10.1016\/j.neuropharm.2026.111013_bib21","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1007\/s12031-025-02366-z","article-title":"More than three decades after discovery of the neuroprotective effect of PACAP, what is still preventing its clinical use?","volume":"75","author":"Cherait","year":"2025","journal-title":"J. Mol. Neurosci."},{"key":"10.1016\/j.neuropharm.2026.111013_bib22","doi-asserted-by":"crossref","DOI":"10.3389\/fncel.2019.00524","article-title":"Pituitary adenylate cyclase-activating polypeptide modulates hippocampal synaptic transmission and plasticity: new therapeutic suggestions for fragile X syndrome","volume":"13","author":"Ciranna","year":"2019","journal-title":"Front. Cell. Neurosci."},{"key":"10.1016\/j.neuropharm.2026.111013_bib23","doi-asserted-by":"crossref","first-page":"2943","DOI":"10.3390\/ijms21082943","article-title":"PACAP modulates the autophagy process in an In vitro model of amyotrophic lateral sclerosis","volume":"21","author":"D'Amico","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.neuropharm.2026.111013_bib24","first-page":"307","article-title":"Neuroprotective potential of three neuropeptides PACAP, VIP and PHI","volume":"57","author":"Dejda","year":"2005","journal-title":"Pharmacol. Rep."},{"key":"10.1016\/j.neuropharm.2026.111013_bib25","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.3390\/jcm8091488","article-title":"Pituitary adenylate cyclase-activating polypeptide: 30 years in research spotlight and 600 million years in service","volume":"8","author":"Denes","year":"2019","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.neuropharm.2026.111013_bib26","article-title":"Pituitary adenylate cyclase activating polypeptide modulates catecholamine storage and exocytosis in PC12 cells","volume":"9","author":"Dong","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.neuropharm.2026.111013_bib27","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.2147\/DDDT.S409373","article-title":"Metformin: a review of potential mechanism and therapeutic utility beyond diabetes","volume":"17","author":"Dutta","year":"2023","journal-title":"Drug Des. Devel. Ther."},{"key":"10.1016\/j.neuropharm.2026.111013_bib28","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.91863","article-title":"Insulin's direct hepatic effect explains the inhibition of glucose production caused by insulin secretion","volume":"2","author":"Edgerton","year":"2017","journal-title":"JCI Insight"},{"key":"10.1016\/j.neuropharm.2026.111013_bib29","doi-asserted-by":"crossref","DOI":"10.2218\/gtopdb\/F67\/2023.1","article-title":"VIP and PACAP receptors in GtoPdb v.2023.1","author":"Fahrenkrug","year":"2023","journal-title":"IUPHAR\/BPS Guide to Pharmacology CITE 2023"},{"key":"10.1016\/j.neuropharm.2026.111013_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2025.106980","article-title":"Cogwheel rigidity in Parkinson's disease: clinical, biomechanical and neurophysiological features","volume":"212","author":"Falletti","year":"2025","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.neuropharm.2026.111013_bib31","doi-asserted-by":"crossref","first-page":"H910","DOI":"10.1152\/ajpheart.00464.2012","article-title":"PACAP causes PAC 1\/VPAC 2 receptor mediated hypertension and sympathoexcitation in normal and hypertensive rats","volume":"303","author":"Farnham","year":"2012","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"10.1016\/j.neuropharm.2026.111013_bib32","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241411843","article-title":"Downregulation of PACAP and the PAC1 receptor in the basal ganglia, Substantia Nigra and centrally projecting edinger\u2013westphal nucleus in the rotenone model of parkinson's disease","volume":"24","author":"Feh\u00e9r","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.neuropharm.2026.111013_bib33","first-page":"1","article-title":"Depression in parkinson's disease: the contribution from animal studies","author":"Fontoura","year":"2017","journal-title":"Parkinsons Dis."},{"key":"10.1016\/j.neuropharm.2026.111013_bib34","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1097\/00001756-200104170-00011","article-title":"BDNF mediates the neuroprotective effect of PACAP-38 on rat cortical neurons","volume":"12","author":"Frechilla","year":"2001","journal-title":"Neuroreport"},{"key":"10.1016\/j.neuropharm.2026.111013_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2024.113716","article-title":"Crosstalk between SIRT1\/Nrf2 signaling and NLRP3 inflammasome\/pyroptosis as a mechanistic approach for the neuroprotective effect of linagliptin in Parkinson's disease","volume":"145","author":"Ghaith","year":"2025","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.neuropharm.2026.111013_bib36","doi-asserted-by":"crossref","DOI":"10.3389\/fncel.2021.663418","article-title":"Pituitary adenylate cyclase-activating polypeptide in learning and memory","volume":"15","author":"Gilmartin","year":"2021","journal-title":"Front. Cell. Neurosci."},{"key":"10.1016\/j.neuropharm.2026.111013_bib37","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.npep.2008.04.003","article-title":"PACAP38 increases vesicular monoamine transporter 2 (VMAT2) expression and attenuates methamphetamine toxicity","volume":"42","author":"Guillot","year":"2008","journal-title":"Neuropeptides"},{"key":"10.1016\/j.neuropharm.2026.111013_bib38","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s12031-010-9364-7","article-title":"Roles for pituitary adenylate cyclase-activating peptide (PACAP) expression and signaling in the bed nucleus of the Stria Terminalis (BNST) in mediating the behavioral consequences of chronic stress","volume":"42","author":"Hammack","year":"2010","journal-title":"J. Mol. Neurosci."},{"key":"10.1016\/j.neuropharm.2026.111013_bib39","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1001\/jamaneurol.2014.3625","article-title":"Association of pituitary adenylate cyclase\u2013activating polypeptide with cognitive decline in mild cognitive impairment due to alzheimer disease","volume":"72","author":"Han","year":"2015","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.neuropharm.2026.111013_bib40","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1212\/WNL.0000000000000417","article-title":"Pituitary adenylate cyclase\u2013activating polypeptide is reduced in Alzheimer disease","volume":"82","author":"Han","year":"2014","journal-title":"Neurology"},{"key":"10.1016\/j.neuropharm.2026.111013_bib41","doi-asserted-by":"crossref","DOI":"10.3389\/fnagi.2021.689939","article-title":"Correlation of decreased Serum pituitary adenylate cyclase-activating polypeptide and vasoactive intestinal peptide levels with non-motor symptoms in patients with parkinson's disease","volume":"13","author":"Hu","year":"2021","journal-title":"Front. Aging Neurosci."},{"key":"10.1016\/j.neuropharm.2026.111013_bib42","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.bbr.2010.02.009","article-title":"Environmental factors during early developmental period influence psychobehavioral abnormalities in adult PACAP-deficient mice","volume":"209","author":"Ishihama","year":"2010","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.neuropharm.2026.111013_bib43","doi-asserted-by":"crossref","first-page":"4788","DOI":"10.3390\/ijms23094788","article-title":"Exploring the pro-phagocytic and anti-inflammatory functions of PACAP and VIP in Microglia: implications for multiple sclerosis","volume":"23","author":"Jansen","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.neuropharm.2026.111013_bib44","author":"Johnson"},{"key":"10.1016\/j.neuropharm.2026.111013_bib45","doi-asserted-by":"crossref","first-page":"5986","DOI":"10.3390\/cimb44120407","article-title":"Antioxidant efficacy of Esculetin against tert-butyl hydroperoxide-induced oxidative stress in HEK293 cells","volume":"44","author":"Jung","year":"2022","journal-title":"Curr. Issues Mol. Biol."},{"key":"10.1016\/j.neuropharm.2026.111013_bib46","author":"Jungling"},{"key":"10.1016\/j.neuropharm.2026.111013_bib47","first-page":"1","article-title":"Nonmotor features in parkinson's disease: what are the Most important associated factors?","author":"Kadastik-Eerme","year":"2016","journal-title":"Parkinsons Dis."},{"key":"10.1016\/j.neuropharm.2026.111013_bib48","doi-asserted-by":"crossref","first-page":"8682","DOI":"10.3390\/ijms22168682","article-title":"Pituitary adenylate cyclase-activating polypeptide (PACAP) in physiological and pathological processes within the gastrointestinal tract: a review","volume":"22","author":"Karpiesiuk","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.neuropharm.2026.111013_bib49","doi-asserted-by":"crossref","DOI":"10.3390\/ijms222010947","article-title":"PACAP and VIP modulate LPS-Induced microglial activation and trigger distinct phenotypic changes in Murine BV2 microglial cells","volume":"22","author":"Karunia","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.neuropharm.2026.111013_bib50","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.neuropharm.2017.08.015","article-title":"Metformin lowers \u03b1-synuclein phosphorylation and upregulates neurotrophic factor in the MPTP mouse model of Parkinson's disease","volume":"125","author":"Katila","year":"2017","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2026.111013_bib51","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1186\/s42466-025-00452-6","article-title":"Environmental toxins in neurodegeneration - a narrative review","volume":"7","author":"Kulcs\u00e1rov\u00e1","year":"2025","journal-title":"Neurol. Res. Pract."},{"key":"10.1016\/j.neuropharm.2026.111013_bib52","doi-asserted-by":"crossref","first-page":"918","DOI":"10.3390\/biomedicines9080918","article-title":"Oxidative stress, mitochondrial dysfunction, and neuroprotection of polyphenols with respect to resveratrol in parkinson's disease","volume":"9","author":"Kung","year":"2021","journal-title":"Biomedicines"},{"key":"10.1016\/j.neuropharm.2026.111013_bib53","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.neuropharm.2015.05.014","article-title":"Characterizations of a synthetic pituitary adenylate cyclase-activating polypeptide analog displaying potent neuroprotective activity and reduced in vivo cardiovascular side effects in a Parkinson's disease model","volume":"108","author":"Lamine","year":"2016","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2026.111013_bib54","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1016\/j.bbadis.2016.01.005","article-title":"Effect of the pituitary adenylate cyclase-activating polypeptide on the autophagic activation observed in in vitro and in vivo models of Parkinson's disease","volume":"1862","author":"Lamine-Ajili","year":"2016","journal-title":"Biochim. Biophys. Acta Mol. Basis Dis."},{"key":"10.1016\/j.neuropharm.2026.111013_bib55","doi-asserted-by":"crossref","first-page":"406","DOI":"10.3390\/biomedicines10020406","article-title":"Signal transduction by VIP and PACAP receptors","volume":"10","author":"Langer","year":"2022","journal-title":"Biomedicines"},{"key":"10.1016\/j.neuropharm.2026.111013_bib56","doi-asserted-by":"crossref","first-page":"369","DOI":"10.5483\/BMBRep.2014.47.7.086","article-title":"Neuroprotective roles of pituitary adenylate cyclase-activating polypeptide in neurodegenerative diseases","volume":"47","author":"Lee","year":"2014","journal-title":"BMB Rep."},{"key":"10.1016\/j.neuropharm.2026.111013_bib57","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.2174\/1568026619666190709092647","article-title":"Targeting the PAC1 receptor for neurological and metabolic disorders","volume":"19","author":"Liao","year":"2019","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.neuropharm.2026.111013_bib58","doi-asserted-by":"crossref","first-page":"8069","DOI":"10.3390\/ijms23158069","article-title":"Targeting VIP and PACAP receptor signaling: new insights into designing drugs for the PACAP subfamily of receptors","volume":"23","author":"Lu","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.neuropharm.2026.111013_bib59","doi-asserted-by":"crossref","first-page":"pyw047","DOI":"10.1093\/ijnp\/pyw047","article-title":"Metformin prevents dopaminergic neuron death in MPTP\/P-Induced mouse model of parkinson's disease via autophagy and mitochondrial ROS clearance","volume":"19","author":"Lu","year":"2016","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.neuropharm.2026.111013_bib61","doi-asserted-by":"crossref","DOI":"10.1242\/dmm.027185","article-title":"Pituitary adenylate cyclase-activating polypeptide (PACAP) has neuroprotective function in dopamine-based neurodegeneration developed in two parkinsonian models","author":"Maasz","year":"2016","journal-title":"Dis. Model. Mech."},{"key":"10.1016\/j.neuropharm.2026.111013_bib62","doi-asserted-by":"crossref","DOI":"10.3390\/ijms222413660","article-title":"Metformin treatment attenuates brain inflammation and rescues PACAP\/VIP neuropeptide alterations in mice Fed a high-fat diet","volume":"22","author":"Mandwie","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.neuropharm.2026.111013_bib63","doi-asserted-by":"crossref","first-page":"9749","DOI":"10.1074\/jbc.M109.043117","article-title":"Pituitary adenylate cyclase-activating polypeptide (PACAP)\/PAC1HOP1 receptor activation coordinates multiple neurotrophic signaling pathways: Akt ACTIVATION THROUGH PHOSPHATIDYLINOSITOL 3-KINASE \u03b3 AND VESICLE ENDOCYTOSIS FOR NEURONAL SURVIVAL","volume":"285","author":"May","year":"2010","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.neuropharm.2026.111013_bib64","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1186\/s12889-024-18653-0","article-title":"Prevalence of Parkinson's disease among adults aged 45 years and older in China: a cross-sectional study based on the China health and retirement longitudinal study","volume":"24","author":"Meng","year":"2024","journal-title":"BMC Public Health"},{"key":"10.1016\/j.neuropharm.2026.111013_bib65","first-page":"1","article-title":"Microbiome signature of Parkinson's disease in healthy and genetically at-risk individuals","volume":"2026","author":"Menozzi","year":"2026","journal-title":"Nat. Med."},{"key":"10.1016\/j.neuropharm.2026.111013_bib66","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/0006-291X(89)91757-9","article-title":"Isolation of a novel 38 residue-hypothalamic polypeptide which stimulates adenylate cyclase in pituitary cells","volume":"164","author":"Miyata","year":"1989","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.neuropharm.2026.111013_bib67","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1097\/MED.0b013e328342568a","article-title":"VIP and PACAP. Recent insights into their functions\/roles in physiology and disease from molecular and genetic studies","volume":"18","author":"Moody","year":"2011","journal-title":"Curr. Opin. Endocrinol. Diabetes Obes."},{"key":"10.1016\/j.neuropharm.2026.111013_bib68","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/s12031-010-9350-0","article-title":"Regulation of oxidative stress by pituitary adenylate cyclase-activating polypeptide (PACAP) mediated by PACAP receptor","volume":"42","author":"Ohtaki","year":"2010","journal-title":"J. Mol. Neurosci."},{"key":"10.1016\/j.neuropharm.2026.111013_bib69","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1007\/s00415-025-13138-5","article-title":"The gut\u2013brain axis in early Parkinson's disease: from prodrome to prevention","volume":"272","author":"Oliver","year":"2025","journal-title":"J. Neurol."},{"key":"10.1016\/j.neuropharm.2026.111013_bib70","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1038\/s41420-025-02845-7","article-title":"Parkinson's associated protein DJ-1 regulates intercellular communication via extracellular vesicles in oxidative stress","volume":"11","author":"Page","year":"2025","journal-title":"Cell Death Discov."},{"key":"10.1016\/j.neuropharm.2026.111013_bib71","doi-asserted-by":"crossref","first-page":"2954","DOI":"10.1158\/0008-5472.CAN-23-3628","article-title":"VPAC2 receptor signaling promotes growth and immunosuppression in pancreatic cancer","volume":"84","author":"Passang","year":"2024","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.neuropharm.2026.111013_bib72","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/s41531-024-00779-y","article-title":"A systematic review and meta-analysis of the prevalence of Parkinson's disease in lower to upper-middle-income countries","volume":"10","author":"Pereira","year":"2024","journal-title":"npj Parkinson's Dis."},{"key":"10.1016\/j.neuropharm.2026.111013_bib73","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1007\/s11357-022-00530-6","article-title":"Examination of pituitary adenylate cyclase-activating polypeptide in Parkinson's disease focusing on correlations with motor symptoms","volume":"44","author":"Pham","year":"2022","journal-title":"GeroScience"},{"key":"10.1016\/j.neuropharm.2026.111013_bib74","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s40266-022-00942-1","article-title":"Depression in patients with parkinson's disease: current understanding of its neurobiology and implications for treatment","volume":"39","author":"Prange","year":"2022","journal-title":"Drugs Aging"},{"key":"10.1016\/j.neuropharm.2026.111013_bib75","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2021.678649","article-title":"Association between diabetes medications and the risk of parkinson's disease: a systematic review and meta-analysis","volume":"12","author":"Qin","year":"2021","journal-title":"Front. Neurol."},{"key":"10.1016\/j.neuropharm.2026.111013_bib77","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.bbr.2003.09.007","article-title":"Pituitary adenylate cyclase activating polypeptide protects dopaminergic neurons and improves behavioral deficits in a rat model of Parkinson's disease","volume":"151","author":"Regl\u0151di","year":"2004","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.neuropharm.2026.111013_bib76","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1007\/s11357-018-0045-8","article-title":"PACAP deficiency as a model of aging","volume":"40","author":"Reglodi","year":"2018","journal-title":"GeroScience"},{"key":"10.1016\/j.neuropharm.2026.111013_bib78","doi-asserted-by":"crossref","first-page":"L56","DOI":"10.1186\/2193-1801-4-S1-L56","article-title":"Neurochemical changes in different brain regions induced by PACAP - relations to neuroprotection","volume":"4","author":"Reglodi","year":"2015","journal-title":"SpringerPlus"},{"key":"10.1016\/j.neuropharm.2026.111013_bib79","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.nbd.2013.02.010","article-title":"PACAP signaling exerts opposing effects on neuroprotection and neuroinflammation during disease progression in the SOD1(G93A) mouse model of amyotrophic lateral sclerosis","volume":"54","author":"Ringer","year":"2013","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.neuropharm.2026.111013_bib80","series-title":"EVALUATION OF SYSTEMICALLY DELIVERED GLYCOPEPTIDES FOR THE TREATMENT OF ACUTE BRAIN INJURY AND PARKINSON\u2019S DISEASE","first-page":"1","author":"Ritter","year":"2024"},{"key":"10.1016\/j.neuropharm.2026.111013_bib81","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/0014-5793(91)80958-6","article-title":"The two forms of the pituitary adenylate cyclase activating polypeptide (PACAP (1\u201327) and PACAP (1\u201338)) interact with distinct receptors on rat pancreatic AR 4\u20102J cell membranes","volume":"286","author":"Robberecht","year":"1991","journal-title":"FEBS Lett."},{"key":"10.1016\/j.neuropharm.2026.111013_bib82","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.neuroscience.2015.03.062","article-title":"Atomoxetine reverses locomotor hyperactivity, impaired novel object recognition, and prepulse inhibition impairment in mice lacking pituitary adenylate cyclase-activating polypeptide","volume":"297","author":"Shibasaki","year":"2015","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuropharm.2026.111013_bib83","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.bbrc.2022.09.079","article-title":"Small-molecule non-peptide antagonists of the PACAP receptor attenuate acute restraint stress-induced anxiety-like behaviors in mice","volume":"631","author":"Shintani","year":"2022","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.neuropharm.2026.111013_bib84","doi-asserted-by":"crossref","DOI":"10.3389\/fncel.2020.00221","article-title":"Protective effects of pituitary adenylate cyclase-activating polypeptide and vasoactive intestinal peptide against cognitive decline in neurodegenerative diseases","volume":"14","author":"Sol\u00e9s-Tarr\u00e9s","year":"2020","journal-title":"Front. Cell. Neurosci."},{"key":"10.1016\/j.neuropharm.2026.111013_bib85","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.3390\/ijms23042120","article-title":"PACAP-38 induces transcriptomic changes in rat trigeminal ganglion cells related to neuroinflammation and altered mitochondrial function presumably via PAC1\/VPAC2 receptor-independent mechanism","volume":"23","author":"Tak\u00e1cs-Lov\u00e1sz","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.neuropharm.2026.111013_bib86","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2023.1118927","article-title":"Role of endocrine PACAP in age-related diseases","volume":"14","author":"Toth","year":"2023","journal-title":"Front. Endocrinol."},{"key":"10.1016\/j.neuropharm.2026.111013_bib87","doi-asserted-by":"crossref","first-page":"827","DOI":"10.3390\/ijms21030827","article-title":"The neuroprotective and biomarker potential of PACAP in human traumatic Brain injury","volume":"21","author":"Toth","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.neuropharm.2026.111013_bib88","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1038\/s41531-024-00778-z","article-title":"Parkinson's families project: a UK-wide study of early onset and familial Parkinson's disease","volume":"10","author":"Towns","year":"2024","journal-title":"npj Parkinson's Dis."},{"key":"10.1016\/j.neuropharm.2026.111013_bib89","doi-asserted-by":"crossref","DOI":"10.1002\/iid3.1346","article-title":"Pharmacological characterization of the antidiabetic drug metformin in atherosclerosis inhibition: a comprehensive insight","volume":"12","author":"Turkistani","year":"2024","journal-title":"Immun. Inflamm. Dis."},{"key":"10.1016\/j.neuropharm.2026.111013_bib60","doi-asserted-by":"crossref","first-page":"3008","DOI":"10.3390\/ijms25053008","article-title":"Acute and chronic exposure to Linagliptin, a selective inhibitor of dipeptidyl Peptidase-4 (DPP-4), has an effect on dopamine, serotonin and noradrenaline level in the striatum and Hippocampus of rats","volume":"25","author":"\u0141upina","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.neuropharm.2026.111013_bib90","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.parkreldis.2021.07.032","article-title":"Digital health technology for non-motor symptoms in people with Parkinson's disease: futile or future?","volume":"89","author":"van Wamelen","year":"2021","journal-title":"Parkinsonism Relat. Disord."},{"key":"10.1016\/j.neuropharm.2026.111013_bib91","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.3390\/biology12071013","article-title":"PACAP and VIP Neuropeptides' and Receptors' effects on appetite, satiety and metabolism","volume":"12","author":"Vu","year":"2023","journal-title":"Biology"},{"key":"10.1016\/j.neuropharm.2026.111013_bib92","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.npep.2008.03.002","article-title":"Neuroprotective effects of PACAP27 in mice model of Parkinson's disease involved in the modulation of KATP subunits and D2 receptors in the striatum","volume":"42","author":"Wang","year":"2008","journal-title":"Neuropeptides"},{"key":"10.1016\/j.neuropharm.2026.111013_bib93","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1186\/s13195-023-01334-2","article-title":"PACAP\u2013Sirtuin3 alleviates cognitive impairment through autophagy in Alzheimer's disease","volume":"15","author":"Wang","year":"2023","journal-title":"Alzheimers Res. Ther."},{"key":"10.1016\/j.neuropharm.2026.111013_bib94","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.neuroscience.2013.03.002","article-title":"PACAP deficiency sensitizes nigrostriatal dopaminergic neurons to paraquat-induced damage and modulates central and peripheral inflammatory activation in mice","volume":"240","author":"Watson","year":"2013","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuropharm.2026.111013_bib95","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.neuroscience.2013.03.002","article-title":"PACAP deficiency sensitizes nigrostriatal dopaminergic neurons to paraquat-induced damage and modulates central and peripheral inflammatory activation in mice","volume":"240","author":"Watson","year":"2013","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuropharm.2026.111013_bib96","doi-asserted-by":"crossref","DOI":"10.3389\/fnagi.2025.1596392","article-title":"The burden of Parkinson's disease, 1990\u20132021: a systematic analysis of the Global Burden of Disease study 2021","volume":"17","author":"Wu","year":"2025","journal-title":"Front. Aging Neurosci."},{"key":"10.1016\/j.neuropharm.2026.111013_bib97","doi-asserted-by":"crossref","first-page":"8881","DOI":"10.3390\/ijms25168881","article-title":"Dipeptidyl peptidase (DPP)-4 inhibitors and pituitary adenylate cyclase-activating polypeptide, a DPP-4 substrate, extend neurite outgrowth of Mouse Dorsal root ganglia neurons: a promising approach in diabetic polyneuropathy treatment","volume":"25","author":"Yamaguchi","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.neuropharm.2026.111013_bib98","doi-asserted-by":"crossref","DOI":"10.1016\/j.npep.2025.102568","article-title":"Pituitary adenylate cyclase-activating polypeptide (PACAP) attenuates diabetic cardiomyopathy via Nrf2\/HO-1 antioxidant signaling and NF-\u03baB-mediated inflammation suppression in streptozotocin-treated mice","volume":"114","author":"Yang","year":"2025","journal-title":"Neuropeptides"},{"key":"10.1016\/j.neuropharm.2026.111013_bib99","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1124\/jpet.106.102236","article-title":"Pituitary adenylate cyclase-activating polypeptide (PACAP) 38 and PACAP4\u20136 are neuroprotective through inhibition of NADPH oxidase: potent regulators of microglia-mediated oxidative stress","volume":"319","author":"Yang","year":"2006","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2026.111013_bib100","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.2337\/db14-0287","article-title":"Repurposing diabetes drugs for brain insulin resistance in alzheimer disease","volume":"63","author":"Yarchoan","year":"2014","journal-title":"Diabetes"},{"key":"10.1016\/j.neuropharm.2026.111013_bib101","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1007\/s10571-025-01544-2","article-title":"Alpha-Synuclein pathophysiology in neurodegenerative disorders: a review focusing on molecular mechanisms and treatment advances in parkinson's disease","volume":"45","author":"Yaribash","year":"2025","journal-title":"Cell. Mol. Neurobiol."},{"key":"10.1016\/j.neuropharm.2026.111013_bib102","article-title":"Exendin-4 and linagliptin attenuate neuroinflammation in a mouse model of Parkinson's disease","author":"Yu","year":"2022","journal-title":"Neural Regen. Res."},{"issue":"1","key":"10.1016\/j.neuropharm.2026.111013_bib103","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/s41531-025-01167-w","article-title":"\u03b1-synuclein in Parkinson's disease: a central point of convergence with depression","volume":"11","author":"Yusuf","year":"2025","journal-title":"npj Parkinson's Dis."},{"key":"10.1016\/j.neuropharm.2026.111013_bib104","first-page":"49","article-title":"Hippocampal PACAP signaling activation triggers a rapid antidepressant response","volume":"11","author":"Zhang","year":"2024","journal-title":"Mil. Med. Res."},{"key":"10.1016\/j.neuropharm.2026.111013_bib105","doi-asserted-by":"crossref","DOI":"10.3389\/fnagi.2025.1655660","article-title":"Gamma-aminobutyric acid associated research in Parkinson's disease: an exploratory trends analysis","volume":"17","author":"Zhou","year":"2026","journal-title":"Front. Aging Neurosci."}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390826001863?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390826001863?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T04:25:16Z","timestamp":1779769516000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390826001863"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":105,"alternative-id":["S0028390826001863"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2026.111013","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"PACAP in Parkinson's disease: A multifunctional neuropeptide at the crossroad of autophagy, inflammation, and metabolic repurposing","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2026.111013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"111013"}}